We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
News

Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
News

Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

The milestone was for the transition of an oncology programme into pre-clinical profiling.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the seventeenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of a compound into pre-clinical profiling. We are pleased the collaborative efforts of teams from Evotec and Boehringer Ingelheim continue to show success in progressing compounds towards the clinic.”

Advertisement